• Salvador Sitjar Martínez de Sas, María Teresa Aguilera de la Fuente, Josep Combalía Romera, Ignacio Menacho Pascual, Susana González Martínez, and Andreu Altés Boronat.
• Medicina de Familia, CAP Les Corts (CAPSE), Barcelona, España. Electronic address: ssitjar@clinic.ub.es.
• Aten Primaria. 2016 May 1; 48 (5): 316324316-24.

ObjectiveTo assess the persistence of treatment with monthly risedronate and know the reasons of persistence and nontherapeutic persistence and the profile of the non-persistent patients.DesingObservational, postmarketin and prospective study.LocationPrimary care, traumatology, rheumatology, gynecology and geriatrics of Catalonia.ParticipantsWomen with osteoporosis treated with monthly risedronate that previously had abandoned weekly bisphosphonate therapy.Main MeasurementsPercentage of patients on persistent monthly risedronate year of their prescription, reasons for persistent and non persistent and profile of non persistent patients in relation to biodemographic data, clinical data and risk factors for fracture.Results289 evaluable patients with a mean age of 68.3. At 12 months of initiation with monthly risedronate, 58.1% of patients remained on treatment. Most frequent reasons for leaving: fear of having side effects and belief that the disease is typical of the age. Reasons remarkable persistence: comfort/ease and dosage. Significant differences were observed between persistent and non-persistent patients relative to: employment status, number of concomitant therapy and height; however the results of possible associated factors must be contextualized within the study characteristics and the difference in size does not seem clinically relevant.ConclusionsThe administration of therapeutic patterns more comfortable as monthly risedronate in osteoporosis, could facilitate persistence in patients improving the effectiveness of the drug. However in that persistence can also influence biodemographic and clinical variables and diverse of various kinds.Copyright © 2015 Elsevier España, S.L.U. All rights reserved.

19 keywords...

hide…